Published in Support Care Cancer on January 26, 2010
Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet (2003) 11.47
Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst (2006) 3.23
The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer (2004) 2.82
Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol (2003) 2.53
Characteristics and correlates of fatigue after adjuvant chemotherapy for breast cancer. J Clin Oncol (1998) 2.27
EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer (2006) 1.96
Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy. J Clin Oncol (2004) 1.86
Erythropoietin biology in cancer. Clin Cancer Res (2006) 1.48
Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy. J Clin Oncol (2004) 1.40
Effects of recombinant erythropoietin on breast cancer-initiating cells. Neoplasia (2007) 1.29
The erythropoietin receptor and its expression in tumor cells and other tissues. Oncologist (2004) 1.23
Management of cancer-related anemia in patients with breast or gynecologic cancer: new insights based on results from the European Cancer Anemia Survey. Oncologist (2005) 1.11
Increased incidence of symptomatic venous thrombosis in patients with cervical carcinoma treated with concurrent chemotherapy, radiation, and erythropoietin. Cancer (2003) 1.11
Expression of erythropoietin and erythropoietin receptor in cervical cancer and relationship to survival, hypoxia, and apoptosis. Clin Cancer Res (2006) 0.97
Does erythropoietin have a dark side? Epo signaling and cancer cells. Sci STKE (2007) 0.96
Erythropoietin: high profile, high scrutiny. J Clin Oncol (2007) 0.94
Anemia correction in malignancy management: threat or opportunity? Gynecol Oncol (2007) 0.90
Erythropoietin stimulates cancer cell migration and activates RhoA protein through a mitogen-activated protein kinase/extracellular signal-regulated kinase-dependent mechanism. J Pharmacol Exp Ther (2007) 0.88
Anemia profiles in patients with lung cancer: what have we learned from the European Cancer Anaemia Survey (ECAS)? Lung Cancer (2005) 0.87
Anemia in lung cancer: clinical impact and management. Clin Lung Cancer (2003) 0.86
Efficacy of epoetin beta on hemoglobin, quality of life, and transfusion needs in patients with anemia due to hormone-refractory prostate cancer--a randomized study. Scand J Urol Nephrol (2001) 0.83
Chemotherapy-induced cognitive dysfunction: a clearer picture. Clin Breast Cancer (2003) 0.82
Effect of treatment with epoetin beta on short-term tumour progression and survival in anaemic patients with cancer: A meta-analysis. Br J Cancer (2006) 0.82
Hemoglobin levels during radiation therapy and their influence on local control and survival of patients with endometrial carcinoma. Oncol Rep (2004) 0.82
Once-weekly treatment of anemia in patients with cancer: a comparative review of epoetins. Oncology (2005) 0.81
The impact of anemia and its treatment on patients with gynecologic malignancies. Semin Oncol (2002) 0.81
Role of epoetin in the management of anaemia in patients with lung cancer. Lung Cancer (2004) 0.80
Weekly epoetin alfa during adjuvant chemotherapy for breast cancer: effect on hemoglobin levels and quality of life. Clin Breast Cancer (2005) 0.79
A new induction schedule of epoetin alfa 40.000 IU in anemic patients with advanced lung cancer. Lung Cancer (2004) 0.78
Darbepoetin alfa: a review of its use in the treatment of anaemia in patients with cancer receiving chemotherapy. Drugs (2006) 0.78
Epoetin alfa increases hemoglobin levels and improves quality of life in anemic geriatric cancer patients receiving chemotherapy. Support Care Cancer (2006) 0.77
Erythropoietin-stimulating agents in oncology. Cancer J (2008) 0.77
Activities of erythropoietin on tumors: an immunological perspective. Eur J Immunol (2007) 0.76
Routine once-weekly darbepoetin alfa administration is cost-effective in lung cancer patients with chemotherapy-induced anemia: a Markov analysis. Lung Cancer (2006) 0.76
Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer: an open-label, randomised controlled trial. Lancet Oncol (2009) 1.70
L1CAM in early-stage type I endometrial cancer: results of a large multicenter evaluation. J Natl Cancer Inst (2013) 1.40
Immediate Administration of Zoledronic Acid Reduces Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women With Early Breast Cancer: 12-month analysis of the E-ZO-FAST trial. Clin Breast Cancer (2011) 1.37
Further evidence for the contribution of the RAD51C gene in hereditary breast and ovarian cancer susceptibility. Breast Cancer Res Treat (2011) 1.24
Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial. J Clin Oncol (2011) 1.19
DNA adduct 8-hydroxydeoxyguanosine, a novel putative marker of prognostic significance in ovarian carcinoma. Int J Gynecol Cancer (2009) 1.10
Surgically staged high-risk endometrial cancer: randomized study of adjuvant radiotherapy alone vs. sequential chemo-radiotherapy. Gynecol Oncol (2008) 1.06
FINHYST 2006--national prospective 1-year survey of 5,279 hysterectomies. Hum Reprod (2009) 0.97
Genome-wide scanning for linkage in Finnish breast cancer families. Eur J Hum Genet (2004) 0.95
Divergent behaviour of oxidative stress markers 8-hydroxydeoxyguanosine (8-OHdG) and 4-hydroxy-2-nonenal (HNE) in breast carcinogenesis. Histopathology (2011) 0.95
Oxidative stress-induced antioxidant enzyme expression is an early phenomenon in ovarian carcinogenesis. Eur J Cancer (2010) 0.94
Randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum. Acta Oncol (2002) 0.93
Treatment of malignant pleural mesothelioma with carboplatin, liposomized doxorubicin, and gemcitabine: a phase II study. J Thorac Oncol (2008) 0.93
Gelatinases A and B (MMP-2 and MMP-9) in endometrial cancer-MMP-9 correlates to the grade and the stage. Gynecol Oncol (2004) 0.89
Tissue polypeptide antigen (TPA), hyaluronan and CA 125 as serum markers in malignant mesothelioma. Anticancer Res (2003) 0.88
Elevated serum 8-OHdG is associated with poor prognosis in epithelial ovarian cancer. Anticancer Res (2011) 0.87
Cutaneous lupus erythematosus after treatment with paclitaxel and bevacizumab for metastatic breast cancer: a case report. J Med Case Rep (2011) 0.86
BMP-4 expression has prognostic significance in advanced serous ovarian carcinoma and is affected by cisplatin in OVCAR-3 cells. Tumour Biol (2011) 0.86
The effect of hospital operative volume, residual tumor and first-line chemotherapy on survival of ovarian cancer - a prospective nation-wide study in Finland. Gynecol Oncol (2009) 0.86
Front-line bevacizumab in serous epithelial ovarian cancer: biomarker analysis of the FINAVAST trial. Anticancer Res (2010) 0.85
Surgical staging, treatment, and follow-up of borderline tumors in different hospital categories: a prospective nationwide survey in Finland. Acta Obstet Gynecol Scand (2007) 0.83
High serum TIMP-1 is associated with adverse prognosis in endometrial carcinoma. Anticancer Res (2008) 0.83
Impact of Epoetin-beta on anemia and health-related quality of life in cancer patients: a prospective observational study using the generic 15D instrument. Anticancer Res (2014) 0.81
Down-regulation of 8-hydroxydeoxyguanosine and peroxiredoxin II in the pathogenesis of endometriosis-associated ovarian cancer. Anticancer Res (2012) 0.80
Azidothymidine and cisplatin increase p14ARF expression in OVCAR-3 ovarian cancer cell line. Toxicol Appl Pharmacol (2006) 0.79
Randomized phase II evaluation of aprinocarsen in combination with gemcitabine and cisplatin for patients with advanced/metastatic non-small cell lung cancer. Invest New Drugs (2005) 0.79
Surgical treatment of ovarian cancer in different hospital categories--a prospective nation-wide study in Finland. Eur J Cancer (2006) 0.79
[Update on current care guidelines: ovarian cancer]. Duodecim (2012) 0.78
The value of sequential serum measurements of gelatinases and tissue inhibitors during chemotherapy in ovarian cancer. Anticancer Res (2007) 0.78
Distinctively low levels of serum 8-hydroxydeoxyguanosine in women with polycystic ovary syndrome. Fertil Steril (2010) 0.77
Effect of estrogen and altered diet hardness on the expression of estrogen receptor alpha and matrix metalloproteinase-8 in rat condylar cartilage. J Orofac Pain (2011) 0.76
A randomised phase III study comparing high-dose chemotherapy to conventionally dosed chemotherapy for stage III ovarian cancer: the Finnish Ovarian Cancer (FINOVA) study. Eur J Cancer (2006) 0.76
Probabilistic sensitivity analysis for evaluating cost-utility of entacapone for Parkinson's disease. Expert Rev Pharmacoecon Outcomes Res (2002) 0.75
[Update on current care guidelines. Diagnosis, treatment and follow-up of cytological changes in the cervix, vagina and vulva]. Duodecim (2010) 0.75
Pharmacokinetics of deramciclane, a novel anxiolytic agent, after intravenous and oral administration. Drugs R D (2003) 0.75
[Decision about DNR for a palliative patient - do I dare to bring up the subject?]. Duodecim (2016) 0.75
[Not Available]. Duodecim (2007) 0.75
[Management of pain in palliative care]. Duodecim (2013) 0.75
Activin B in patients with granulosa cell tumors: serum levels in comparison to inhibin. Acta Obstet Gynecol Scand (2003) 0.75
[Cancer diagnosed during pregnancy]. Duodecim (2012) 0.75
[Abdominal infection unresponsive from antibiotic therapy in middle-aged woman]. Duodecim (2010) 0.75
[Bevacizumab in the treatment of non-small cell lung cancer]. Duodecim (2009) 0.75
Metformin decreases serum 8-hydroxy-2'-deoxyguanosine levels in polycystic ovary syndrome. Fertil Steril (2012) 0.75
[Not Available]. Duodecim (2007) 0.75
[Not Available]. Duodecim (2007) 0.75
Pharmacological Preconditioning with Diazoxide in the Experimental Hypothermic Circulatory Arrest Model. Heart Surg Forum (2017) 0.75